Progress, Potential, and Possibilities Podcast / Show

Send us a textDr. David Carmouche, MD is Senior Vice President of Omnichannel Care at Walmart, where he leads the fleet of Walmart Health centers, Walmart Health Virtual Care, Walmart’s work to address Social Determinants of Health, and all new omnichannel healthcare offerings ( https://www.walmarthealth.com/ ). He joined Walmart in 2021, bringing a unique combination of provider, payer, and integrated delivery network experience - serving as a physician, an executive for an insurance company, and as a leader in a regional health system. Dr. Carmouche joined Walmart from Ochsner Health, the largest nonprofit academic healthcare system in the Gulf South, where he served as EVP, Value-based Care and Network Operations; President, Ochsner Health Network; and Executive Director, Ochsner Accountable Care Network. Prior to joining Ochsner Health, Dr. Carmouche was Chief Medical Officer and Executive Vice President of External Operations for Blue Cross and Blue Shield of Louisiana, where he introduced the company’s first value-based care contracts. As the first lipidologist in Louisiana and a Fellow of the National Lipid Association, he practiced preventative cardiology in Baton Rouge through 2012, where he built a large, multidisciplinary internal medicine and preventive cardiology practice as Director of the Center for Cardiovascular Disease Prevention at the Baton Rouge Clinic. He also championed an Epic electronic medical record (EMR) single instance implementation across three entities. Dr. Carmouche attended Tulane University where he studied biology, and LSU Medical School in New Orleans. Board-certified in Internal Medicine, he completed his residency at the University of Alabama at Birmingham where he later served as Chief Resident. He serves as President of the Board of the Consortium for Southeastern Healthcare Quality, and he serves on the advisory board at Stellar Health. He is a board observer and advisor for a New Orleans-based startup, Ready, and he serves nationally as a board member for the National Association of Accountable Care Organizations. Support the show

Send us a textDr. Mark Bailey, Ph.D. is the Department Chair of Cyber Intelligence and Data Science (CIDS) at the Oettinger School of Science and Technology Intelligence, and the Co-Director at the Data Science Intelligence Center, at the U.S. National Intelligence University ( https://ni-u.edu/wp/ ). The National Intelligence University (NIU) is a federally chartered research university in Bethesda, Maryland, operated by and for the United States Intelligence Community (IC), as its staff college of higher learning in fields of study central to the profession of intelligence and national security. The Anthony G. Oettinger School of Science and Technology Intelligence (MSTI) prepares students for careers specifically at the forefront of science and technology intelligence. Prior to this role, Dr. Bailey served in several roles in the U.S. Department of Defense, Department of State, and the Intelligence Community, including: as a Biochemical Intelligence Analyst and Medical Support Officer in the United States Army Reserve (where he also has the title of Major); as a Chemical and Biological Foreign Policy Advisor within the Office of Missile, Biological and Chemical Nonproliferation, U.S. Department of State; as a Department Chief at USAMRIID; and as a Chemical Engineer at National Institute of Standards and Technology. Dr. Bailey has Master of Science (MS), in Technology Intelligence, from National Intelligence University. He also has a Bachelor of Science in Chemical Engineering from University of Pittsburgh, and an MS in Chemical Engineering and a Ph.D. in Bioengineering from University of Kansas. Support the show

Send us a textDr. Rita Baranwal, Ph.D. is Senior Vice President of the Energy Systems business unit of Westinghouse Electric Company, which is the nuclear power unit of Westinghouse, where her core focus is in leading the team developing and deploying their AP300 Small Modular Nuclear Reactor ( https://www.westinghousenuclear.com/Portals/0/about-2020/leadership/WEC_Bio_Dr._Rita_Baranwal_JUL22.pdf ). Dr. Baranwal recently served Chief Technology Officer of the organization, where she led the company’s global research and development investments, spearheading their technology strategy to advance the company’s nuclear innovation, and drove next-generation solutions for existing and new markets. Dr. Baranwal’s appointment to this CTO role in 2022 marked a return to Westinghouse where she worked for nearly a decade in leadership positions in the Global Technology Development, Fuel Engineering, and Product Engineering groups. Prior to rejoining Westinghouse, Dr. Baranwal served as Assistant Secretary for the U.S. Department of Energy’s (DOE) Office of Nuclear Energy where she directed the R&D portfolio across current and advanced nuclear technologies while collaborating across nuclear utilities, national labs, reactor developers, academia and government stakeholders. She has also held senior leadership roles with the Idaho National Laboratory as Director of the Gateway for Accelerated Innovation in Nuclear (GAIN), and most recently was the Chief Nuclear Officer and Vice President of Nuclear for the Electric Power Research Institute (EPRI). Prior to joining Westinghouse, Dr. Baranwal was a manager in Materials Technology at Bechtel Bettis, Inc. where she led and conducted R&D in advanced nuclear fuel materials for US Naval Reactors. Dr. Baranwal is a Fellow of the American Nuclear Society. She has a bachelor’s degree from Massachusetts Institute of Technology (MIT) in materials science and engineering and a master’s degree and Ph.D. in the same disciplines from the University of Michigan. Support the show

Send us a textDr. Michael Ott, Ph.D. is Senior Vice President and Chief Research and Development Officer of The Clorox Company ( https://www.thecloroxcompany.com/company/corporate-governance/executive-team/michael-ott/ ). In this role, which he assumed in June 2022, Dr. Ott leads global research and development, and is responsible for product development and innovation, from concept to commercialization, and oversees the company’s stewardship activities and technical capability areas. Dr. Ott has spent his entire professional career at Clorox, supporting nearly every part of the business. Prior to his current assignment, he was Vice President of Research and Development – Specialty, helping reset the business through the creation of innovation platforms such as Fresh Step Outstretch cat litter, Glad with Clorox trash bags and Hidden Valley Special Sauce. During this time, he also served as the company’s interim Chief Sustainability Officer, working with the businesses to achieve the company’s packaging and emissions goals. Previously, Dr. Ott was Vice President of Research and Development for the Cleaning, International and CloroxPro divisions. For more than a decade, he led initiatives resulting in significant expansion of the company’s Home Care and Professional businesses. Starting as a bench scientist in 1996, Dr. Ott moved to the Product Supply Organization’s Global Strategic Sourcing team before returning to research and development to help launch the company’s Open Innovation capability. Dr. Ott serves as chair and chief volunteer officer of the board of directors for the Boys and Girls Club of Oakland, California, and coaches Pop Warner youth football in West Oakland. Dr. Ott holds a doctorate in chemistry from the University of California, Santa Barbara and a bachelor’s degree in chemistry from Villanova University. Support the show

Send us a textDr. Elica Kyoseva, Ph.D. is the Quantum for Bio Program Director, at Wellcome Leap ( https://wellcomeleap.org/our-team/elicakyoseva/ ), a $40M +$10M program focused on identifying, developing, and demonstrating biology and healthcare applications that will benefit from the quantum computers expected to emerge in the next 3-5 years. Wellcome Leap was established with $300 million in initial funding from the Wellcome Trust, the UK charitable foundation, to accelerate discovery and innovation for the benefit of human health, focusing on build bold, unconventional programs and fund them at scale—specifically programs that target global human health challenges, with the goal of achieving breakthrough scientific and technological solutions. Dr. Kyoseva completed her Ph.D. in Quantum Optics and Information, at Sofia University in Bulgaria, and then moved to the Center for Quantum Technologies in Singapore as a postdoc. Three years later, she established her own research group in Quantum Engineering at the Singapore University of Tech & Design and subsequently spent a year at MIT (Cambridge, USA) as a Research Fellow in the Nuclear Science and Engineering Department doing research on quantum control and engineering. In 2016, Dr. Kyoseva was awarded a Marie Curie fellowship for research excellence by the European Commission with which she relocated to Tel Aviv, Israel and continued her research in robust control methods for Quantum Computing at Tel Aviv University. Since the beginning of 2020 she served as an Entrepreneur in Residence and Advisor at a venture capital firm and was instrumental for their investments in quantum computing startups. In September 2020, she took a senior role with Boehringer Ingelheim to develop applications of quantum algorithms to the drug discovery process working on the cutting edge of applied quantum computing technologies to improve the lives of both humans and animals. Additionally to her scientific career, Dr. Kyoseva is very passionate about ending gender inequality in the STEM fields and served as a STEM Ambassador to the UN Women Singapore Committee for 2 years. Currently, she is the Managing Director for Israel of the global non-profit organization Girls in Tech and on the Advisory Board of She Quantum and works towards encouraging more girls and women to pursue a career in Quantum Computing. Support the show

Send us a textEmilio Alonso-Mendoza, J.D., CFRE is the Chief Executive Officer of the Alexander Graham Bell Association (AG Bell) for the Deaf and Hard of Hearing ( https://www.agbell.org/ ) and has served in this role since April 2014, guiding the organization in international growth and innovation. Created in 1890, the mission of the Alexander Graham Bell Association for the Deaf and Hard of Hearing is to work globally to ensure that people who are deaf and hard of hearing can hear and talk. It is headquartered in Washington, D.C., with chapters located throughout the United States and a network of international affiliates. Prior to this role, Mr. Alonso-Mendoza served in multiple President and CEO roles for Take Stock in Children; the Catholic Community Foundation; the Children’s Home Society of Florida, and the National Parkinson’s Foundation, where he established 52 centers for research throughout the US, Europe, South America, and Asia. Mr. Alonso-Mendoza has served, or currently serves, on the board of directors at Children’s Home Society Foundation, Leadership Learning Center, St Vincent de Paul Seminary and the League Against Cancer, among others. Mr. Alonso-Mendoza received a Juris Doctor degree from the University of Miami School of Law and holds a bachelor’s degree in journalism from the same institution. He also holds a professional credential as a Certified Fundraising Executive from CFRE International. Support the show

Send us a textDr. Anders Nordström, MD is Ambassador for Global Health at the Ministry for Foreign Affairs of Sweden ( https://www.government.se/government-of-sweden/ministry-for-foreign-affairs/ ), Member of the Virchow Foundation for Global Health Council and Secretary of the World Health Organization's Independent Panel for Pandemic Preparedness and Response (IPPPR). A trained physician at the Karolinska Institute in the field of national and international health policy, planning and strategic leadership, Dr. Nordström has held the position of Ambassador for Global Health at the Swedish Ministry for Foreign Affairs since September 2010. Dr. Nordström also has served as Assistant Director-General and acting Director-General for the World Health Organization (WHO) as well as the Head of the WHO Country Office in Sierra Leone. In addition, Dr. Nordström is a member of the Commission for Universal Health convened by Chatham House. Previously, Dr. Nordström was the Chief Executive Officer of SIDA (the Swedish International Development Cooperation Agency), worked for the Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva, and for the Red Cross, and has been posted internationally in a diverse range of countries from Zambia to Cambodia to Iran. Support the show

Send us a textDr. Leroy Hood, MD, Ph.D. ( https://isbscience.org/bio/leroy-hood/ ) is Co-Founder, Chief Strategy Officer and Professor, at the Institute of Systems Biology (ISB) in Seattle, as well as CEO of Phenome Health ( https://phenomehealth.org/ ), a nonprofit organization dedicated to delivering value through health innovation focused on his P4 model of health (Predictive, Preventive, Personalized and Participatory) where a patient’s unique individuality is acknowledged, respected, and leveraged for the benefit of everyone. Dr. Hood, who is a world-renowned scientist and recipient of the National Medal of Science in 2011, co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000-2017. In 2016, ISB affiliated with Providence St. Joseph Health (PSJH) and Dr. Hood became PSJH’s Senior Vice President and Chief Science Officer. Dr. Hood is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three. Dr. Hood received his MD from Johns Hopkins University School of Medicine and his PhD in biochemistry from Caltech. Dr. Hood was a faculty member at Caltech from 1967-1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments that paved the way for the Human Genome Project’s successful mapping and understanding of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood founded and chaired the Department of Molecular Biotechnology at the University of Washington, the first academic department devoted to cross-disciplinary biology. Dr. Hood has co-founded 17 biotech companies including Amgen, Applied Biosystems, Rosetta and Arivale. His many national and international awards include the Lasker Prize, the Kyoto Prize, and the National Medal of Science. Dr. Hood's new book "The Age of Scientific Wellness: Why the Future of Medicine Is Personalized, Predictive, Data-Rich, and in Your Hands" is available on all major book sellers. Support the show

Send us a textEPISODE DISCLAIMER - At any time during this episode when anyone says Merck, in any context, it shall always be referring to Merck KGaA, Darmstadt, Germany. Dr. Emre Ozcan, Ph.D. is VP, Global Head of Digital Health, at Merck KGaA, Darmstadt, Germany ( https://www.emdgroup.com/en ), where he brings 15+ years experience in biopharma, med-tech and healthcare consulting with experience across strategy, research, marketing, and operations in several therapeutic areas. In his current role, he holds the accountability for the design and end-to-end delivery of digital health solutions to support Merck KGaA, Darmstadt, Germany franchise strategies and shape the architecture of the offering "around the drug" including devices and diagnostics. Prior to joining Merck KGaA, Darmstadt, Germany, Dr. Ozcan was a Junior Partner at Boston Consulting Group. He holds a BA degree from Yale University; and MPhil and PhD from Oxford University. Walid Mehanna is Group Data Officer And Senior Vice President, Merck KGaA, Darmstadt, Germany, where he has responsibility for driving Data & Analytics strategy, implementation, architecture, governance, and culture across all its businesses. Previously, Mr. Mehanna served as Mercedes-Benz Car’s first Chief Data Officer and prior to joining Mercedes Benz, he spent over a decade at Horváth, serving as a Consultant, Senior Project Manager and later as Principal of Business Intelligence & Big Data. With more than twenty-five years of technology experience and twenty years in consulting and major corporations, he enjoys working at the intersection of business and technology in all domains. Support the show

Send us a textEPISODE DISCLAIMER - The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent. Dr. Devi SenGupta, MD, MPhil, is Executive Director of Clinical Development at Gilead Sciences ( https://www.gilead.com/ ), where she leads the company’s HIV cure development program and during her time at the company has led multiple HIV treatment and cure studies. As head of the HIV cure program, she provides strategic direction for cross-functional internal teams and external multi-stakeholder collaborations developing combination approaches aimed at achieving long-term HIV remission. Before joining Gilead in 2015, Dr. SenGupta was a physician scientist leading translational HIV immunology research as an Assistant Professor at the University of California, San Francisco (UCSF). Her NIH-funded program focused on identifying novel strategies to enhance cellular immunity against HIV. Dr. SenGupta received her Bachelor of Arts in psychology and biology at Harvard University, MPhil. in neuropsychology at Cambridge University, UK, and MD at the University of Washington School of Medicine. She completed her internal medicine residency at Johns Hopkins Hospital and infectious diseases fellowship at UCSF. Support the show